Capricor Therapeutics (CAPR) shares soared 12% in the last trading session to close at $6.92. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 14.3% loss over the past four weeks.The sharp rise in CAPR shares can be attributed to the company’s recent regulatory progress and growing optimism around upcoming clinical milestones. Management’s prior update confirming FDA alignment on trial endpoints has strengthened expectations for a ...